{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T05:40:18Z","timestamp":1737783618070,"version":"3.33.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,24]]},"DOI":"10.7759\/cureus.77932","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T01:12:05Z","timestamp":1737767525000},"source":"Crossref","is-referenced-by-count":0,"title":["Carcinoid Heart Disease: A Classic One, But Not Always Remembered"],"prefix":"10.7759","author":[{"given":"Pamela","family":"Ram\u00edrez-Rangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge  D","family":"Rodr\u00edguez-Esparza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xochitl A","family":"Ortiz-Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel  E","family":"Vargas-Ahumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Herrera-Goepfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin DM","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al.. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017, 18:525-34. 10.1016\/S1470-2045(17)30110-9","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"14","author":"Davar J","year":"2017","unstructured":"Davar J, Connolly HM, Caplin ME, et al.. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017, 14:1288-304. 10.1016\/j.jacc.2016.12.030","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.03.018","article-title":"Carcinoid heart disease: current understanding and future directions","volume":"167","author":"Patel C","year":"2014","unstructured":"Patel C, Mathur M, Escarcega RO, Bove AA. Carcinoid heart disease: current understanding and future directions. Am Heart J. 2014, 167:789-95. 10.1016\/j.ahj.2014.03.018","journal-title":"Am Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000507847","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management","volume":"146","author":"Jin C","year":"2021","unstructured":"Jin C, Sharma AN, Thevakumar B, et al.. Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management. Cardiology. 2021, 146:65-73. 10.1159\/000507847","journal-title":"Cardiology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.12.025","article-title":"Risk factors for the development and progression of carcinoid heart disease","volume":"107","author":"Bhattacharyya S","year":"2011","unstructured":"Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011, 107:1221-6. 10.1016\/j.amjcard.2010.12.025","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/ije-2019-0001","article-title":"The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far","volume":"6","author":"Ewang-Emukowhate M","year":"2019","unstructured":"Ewang-Emukowhate M, Nair D, Caplin M. The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far. Int J Endocr Oncol. 2019, 6:0. 10.2217\/ije-2019-0001","journal-title":"Int J Endocr Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya S","year":"2008","unstructured":"Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008, 102:938-42. 10.1016\/j.amjcard.2008.05.047","journal-title":"Am J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.109.886846","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI","volume":"3","author":"Bhattacharyya S","year":"2010","unstructured":"Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010, 3:103-11. 10.1161\/CIRCIMAGING.109.886846","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jer316","article-title":"EAE\/ASE recommendations for image acquisition and display using three-dimensional echocardiography","volume":"13","author":"Lang RM","year":"2012","unstructured":"Lang RM, Badano LP, Tsang W, et al.. EAE\/ASE recommendations for image acquisition and display using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging. 2012, 13:1-46. 10.1093\/ehjci\/jer316","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0413","article-title":"Multidisciplinary team management of carcinoid heart disease","volume":"8","author":"Steeds R","year":"2019","unstructured":"Steeds R, Sagar V, Shetty S, et al.. Multidisciplinary team management of carcinoid heart disease. Endocr Connect. 2019, 8:R184-99. 10.1530\/EC-19-0413","journal-title":"Endocr Connect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2008.10.013","article-title":"Cardiovascular magnetic resonance imaging in the assessment of carcinoid heart disease","volume":"64","author":"Sandmann H","year":"2009","unstructured":"Sandmann H, Pakkal M, Steeds R. Cardiovascular magnetic resonance imaging in the assessment of carcinoid heart disease. Clin Radiol. 2009, 64:761-6. 10.1016\/j.crad.2008.10.013","journal-title":"Clin Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04918-4","article-title":"[(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients","volume":"47","author":"Pauwels E","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, et al.. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020, 47:3033-46. 10.1007\/s00259-020-04918-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.257659","article-title":"Dual PET imaging in bronchial neuroendocrine neoplasms: the NETPET score as a prognostic biomarker","volume":"62","author":"Chan DL","year":"2021","unstructured":"Chan DL, Ulaner GA, Pattison D, et al.. Dual PET imaging in bronchial neuroendocrine neoplasms: the NETPET score as a prognostic biomarker. J Nucl Med. 2021, 62:1278-84. 10.2967\/jnumed.120.257659","journal-title":"J Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27460","article-title":"Prognostic value of a three-scale grading system based on combining molecular imaging with (68)Ga-DOTATATE and (18)F-FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias","volume":"11","author":"Karfis I","year":"2020","unstructured":"Karfis I, Marin G, Levillain H, et al.. Prognostic value of a three-scale grading system based on combining molecular imaging with (68)Ga-DOTATATE and (18)F-FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias. Oncotarget. 2020, 11:589-99. 10.18632\/oncotarget.27460","journal-title":"Oncotarget"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.06.27","article-title":"Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms","volume":"6","author":"Kyriakopoulos G","year":"2018","unstructured":"Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018, 6:252. 10.21037\/atm.2018.06.27","journal-title":"Ann Transl Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca A","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, et al.. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024, 36:e13423. 10.1111\/jne.13423","journal-title":"J Neuroendocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke A","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al.. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009, 27:4656-63. 10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4089","article-title":"Final progression-free survival (PFS) analyses for lanreotide autogel\/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): the CLARINET extension study","volume":"e35","author":"Wolin EM","year":"2017","unstructured":"Wolin EM, Pavel M, Cwikla JB, et al.. Final progression-free survival (PFS) analyses for lanreotide autogel\/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): the CLARINET extension study. J Clin Oncol. 2017, e35:4089. 10.1200\/JCO.2017.35.15_suppl.4089","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2010.10.035","article-title":"Outcomes, risks and complications of cardiac surgery for carcinoid heart disease","volume":"40","author":"Bhattacharyya S","year":"2011","unstructured":"Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J. Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg. 2011, 40:168-72. 10.1016\/j.ejcts.2010.10.035","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329150-carcinoid-heart-disease-a-classic-one-but-not-always-remembered","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T01:12:07Z","timestamp":1737767527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329150-carcinoid-heart-disease-a-classic-one-but-not-always-remembered"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.77932","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}